Leon Moulder, Jr. Acquires 50,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. bought 50,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were bought at an average cost of $16.38 per share, with a total value of $819,000.00. Following the purchase, the chief executive officer directly owned 316,155 shares in the company, valued at approximately $5,178,618.90. This trade represents a 18.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Zenas BioPharma Trading Down 2.0%

Zenas BioPharma stock opened at $16.08 on Friday. Zenas BioPharma, Inc. has a 12 month low of $5.83 and a 12 month high of $44.60. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. The stock has a market cap of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. The company’s fifty day simple moving average is $34.94 and its 200-day simple moving average is $24.11.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Institutional Investors Weigh In On Zenas BioPharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP lifted its position in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the last quarter. Two Sigma Investments LP increased its position in Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock worth $452,000 after buying an additional 765 shares during the period. Bank of America Corp DE lifted its holdings in shares of Zenas BioPharma by 5.8% during the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after buying an additional 818 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Zenas BioPharma in the third quarter valued at approximately $30,000. Finally, Rhumbline Advisers grew its stake in shares of Zenas BioPharma by 7.6% in the third quarter. Rhumbline Advisers now owns 21,214 shares of the company’s stock worth $471,000 after acquiring an additional 1,493 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have commented on ZBIO. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Evercore ISI initiated coverage on Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Finally, Citigroup increased their price objective on Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma currently has an average rating of “Moderate Buy” and an average price target of $43.14.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO insider purchases — Leon Moulder Jr. bought a total of ~100,000 shares across Jan. 7–9 (50k @ $16.38, 30k @ $16.30, 20k @ $16.55), spending roughly $1.63M and raising his direct stake to ~366,155 shares (~$6.06M value). Large, repeated CEO buys often signal management confidence and can attract buying interest. Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock
• Positive Sentiment: Analyst backdrop is constructive — brokerages’ consensus rating sits at “Moderate Buy” with several buy/outperform opinions and elevated average price targets, which can support demand if sentiment persists. Zenas BioPharma Given Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: SEC filings confirm timing and price — multiple Form 4 disclosures document the CEO’s transactions, providing transparency on cost basis and validating the insider activity for investors doing due diligence. SEC filing confirming insider purchases
• Neutral Sentiment: Mixed analyst and price‑target dispersion — while many firms are bullish, some recent revisions (e.g., Morgan Stanley trimming its target) create varied upside expectations that can mute a clear consensus move. MarketBeat ZBIO analyst summary
• Negative Sentiment: Litigation/investigation headline risk — Pomerantz LLP issued an investor alert investigating Zenas, which can trigger short‑term volatility, legal costs, and investor caution until the scope and findings are clarified. Pomerantz investigates Zenas BioPharma

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.